{"Clinical Trial ID": "NCT00191269", "Intervention": ["INTERVENTION 1:", "Level 1 dose", "- gemcitabine at 1000 mg/m2 administered intravenously for 30-60 minutes on days 1 and 8 in each 3 week (21 day) study cycle.", "INTERVENTION 2:", "Level 2 dose", "- gemcitabine at 1250 mg/m2 administered intravenously for 30-60 minutes on days 1 and 8 in each 3-week (21-day) study cycle."], "Eligibility": ["Incorporation criteria:", "Histologically and/or cytologically confirmed breast cancer", "Has received prior chemotherapy for metastatic breast cancer with anthracycline and taxane diet", "Have at least one measurable region", "PS: 0-1", "To have an adequate function of the organ (bone marrow, liver and kidney function)", "- Exclusion criteria:", "To have pore pneumonia or pulmonary fibrosis", "To have inflammatory carcinoma", "Within 28 days of the last chemotherapy or radiotherapy, 14 days after the last hormone/immunotherapy or 7 days after the surgery", "\u2022 Have brain metastases with symptoms", "\u2022 Severe complication (heart infarction, infection, drug hypersensitivity or diabetes)"], "Results": ["Performance measures:", "Response of tumours", "The best response recorded from the start of treatment to the progression or recurrence of the disease using the solid tumour response assessment criteria (RECIST), which defines when participants improve (\"response\"), remain the same (\"stable\") or worsen (\" progression\") during treatment.", "Time frame: basis for measuring progressive disease", "Results 1:", "Title of arm/group: Dose Level 1", "Description of the arm/group: Gemcitabine 1000 mg/m2 administered intravenously for 30-60 minutes on days 1 and 8 in each 3-week (21-day) study cycle.", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial response: 0", "A long stable disease: 1", "Stable disease: 1", "Progressive diseases: 2", "Not elected: 2", "Results 2:", "Title of arm/group: Dose Level 2", "Description of the arm/group: Gemcitabine at 1250 mg/m2 administered intravenously for 30-60 minutes on days 1 and 8 in each 3-week (21-day) study cycle.", "Total number of participants analysed: 62", "Type of measurement: Number", "Unit of measure: Participants Complete response: 1", "Partial reply: 4", "Long Stable Sickness: 4", "Stable disease: 16", "Progressive diseases: 32", "Not elected: 5"], "Adverse Events": ["Undesirable Events 1:", "Total: 1", "Acute heart failure 0/6 (0.00 %)", "Category 0/6 (0.00 %)", "Cellulite 1/6 (16.67%)", "Infection 0/6 (0.00 %)", "Increased lactate dehydrogenase in blood 0/6 (0.00 %)", "Anorexia 0/6 (0.00 %)", "- Femur fracture 0/6 (0.00 %)", "- Brain edema 0/6 (0.00 %)", "Dyspnoea 1/6 (16.67%)", "Acute respiratory impairment 0/6 (0.00 %)", "- Venous catheterization 0/6 (0.00 %)", "The Raynaud phenomenon 0/6 (0.00 %)", "Adverse Events 2:", "Total: 10", "Acute heart failure 1/62 (1.61%)", "Cataract 1/62 (1.61%)", "Cellulite 1/62 (1.61%)", "Infection 1/62 (1.61%)", "Increased lactate dehydrogenase 1/62 (1.61%)", "Anorexia 1/62 (1.61%)", "- Fracture of the femur 1/62 (1.61%)", "- Brain edema 1/62 (1.61%)", "- Dyspnoea 0.62 (0.00 %)", "Acute respiratory impairment 1/62 (1.61%)", "- Venous catheterization 2/62 (3.23%)"]}